Ohr Pharmaceutical Inc (OHRP):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Ohr Pharmaceutical Inc (OHRP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8048
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ohr Pharmaceutical Inc (Ohr), formerly BBM Holdings Inc, is a pharmaceutical company that develops novel therapies for ophthalmic diseases. The company offers products such as squalamine lactate ophthalmic solution and SKS sustained release technology products. Its squalamine lactate ophthalmic solution is used in wet age-related macular degeneration, retinal vein occlusion, proliferative diabetic retinopathy and diabetic macular edema indications. Ohr has a sustained-release micro-fabricated micro-particle ocular drug delivery platform technology that utilizes hydrogel template approach to prepare microparticles or other configurations. The company also conducts programs for the treatment of ocular conditions including primary open angle glaucoma, steroid-induced glaucoma, ocular allergy, and retinal diseases. It operates through its research facilities in San Diego, the US. Ohr is headquartered in New York, the US.

Ohr Pharmaceutical Inc (OHRP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Ohr Pharma Completes Acquisition of Ophthalmology Assets from SKS Ocular 10
Partnerships 11
Ohr Pharma Forms Joint Venture With Cold Spring Harbor Lab 11
Licensing Agreements 12
Vitrisa Therapeutics Enters into Option Agreement with Ohr Pharma 12
Equity Offering 13
Ohr Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 13
Ohr Pharma Raise USD14.2 Million in Public Offering of Shares and Warrants 14
Ohr Pharmaceutical Raises USD7.8 Million in Public Offering of Shares and Warrants 16
Ohr Pharma Raises USD29 Million Public Offering of Shares 17
Ohr Pharma Completes Private Placement Of Shares For US$18 Million 19
Ohr Pharma Raises USD0.4 Million in Private Placement of Shares 20
Ohr Pharma Completes Private Placement Of Shares For US$5 Million Upon Exercise Of Warrants 21
Ohr Pharma Completes Private Placement Of Shares For US$2.9 Million Upon Exercise Of Warrants 22
Ohr Pharmaceutical Inc – Key Competitors 23
Ohr Pharmaceutical Inc – Key Employees 24
Ohr Pharmaceutical Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Joint Venture 25
Recent Developments 26
Financial Announcements 26
Aug 14, 2018: Ohr Pharmaceutical reports fiscal third quarter 2018 financial results 26
May 15, 2018: Ohr Pharmaceutical Announces Fiscal Second Quarter 2018 Financial Results 27
Feb 14, 2018: Ohr Pharmaceutical Reports Q1 Fiscal 2018 Financial Results 28
Dec 15, 2017: Ohr Pharmaceutical Reports Fiscal Year 2017 Financial Results 29
Aug 08, 2017: Ohr Pharmaceutical Announces Fiscal Third Quarter 2017 Earnings 30
May 11, 2017: Ohr Pharmaceutical Announces Fiscal Second Quarter 2017 Earnings 32
Feb 14, 2017: Ohr Pharmaceutical Announces Strategic Update and Fiscal First Quarter 2017 Earnings 33
Corporate Communications 34
May 11, 2017: Ohr Pharmaceutical Announces Appointment of Hon. Mike Ferguson as Chairman of the Board of Directors 34
Product News 35
01/05/2018: Ohr Pharmaceutical Announces Efficacy Results from the MAKO Study in Wet-AMD 35
Clinical Trials 36
Apr 10, 2017: Ohr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet-AMD 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ohr Pharmaceutical Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ohr Pharma Completes Acquisition of Ophthalmology Assets from SKS Ocular 10
Ohr Pharma Forms Joint Venture With Cold Spring Harbor Lab 11
Vitrisa Therapeutics Enters into Option Agreement with Ohr Pharma 12
Ohr Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 13
Ohr Pharma Raise USD14.2 Million in Public Offering of Shares and Warrants 14
Ohr Pharmaceutical Raises USD7.8 Million in Public Offering of Shares and Warrants 16
Ohr Pharma Raises USD29 Million Public Offering of Shares 17
Ohr Pharma Completes Private Placement Of Shares For US$18 Million 19
Ohr Pharma Raises USD0.4 Million in Private Placement of Shares 20
Ohr Pharma Completes Private Placement Of Shares For US$5 Million Upon Exercise Of Warrants 21
Ohr Pharma Completes Private Placement Of Shares For US$2.9 Million Upon Exercise Of Warrants 22
Ohr Pharmaceutical Inc, Key Competitors 23
Ohr Pharmaceutical Inc, Key Employees 24
Ohr Pharmaceutical Inc, Joint Venture 25

List of Figures
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ohr Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Ohr Pharmaceutical Inc (OHRP):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cyclo Therapeutics Inc (CTDH):企業の財務・戦略的SWOT分析
    Summary Cyclo Therapeutics Inc (Cyclo Therapeutics), formerly CTD Holdings Inc, is a biotechnology company that develops and manufactures cyclodextrin-based drugs. It is investigating Trappsol Cyclo, an orphan drug against Niemann-Pick disease type C and Alzheimer’s disease. The company also develop …
  • Western Farmers Electric Cooperative:発電所・企業SWOT分析
    Western Farmers Electric Cooperative - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Petoro AS-石油・ガス分野:企業M&A・提携分析
    Summary Petoro AS (Petoro) is an oil and gas asset management company. The company manages Norwegian state’s direct financial interests (SDFI) in Norwegian Continental Shelf (NCS) oil and gas assets. It has the responsibility for and to attend to the commercial aspects related to the state's direct …
  • University of Wisconsin Madison:製薬・医療:M&Aディール及び事業提携情報
    Summary University of Wisconsin Madison (UW-Madison), a subsidiary of University of Wisconsin System is an educational and research institution that provides undergraduate and postgraduate courses. The institution offers courses in various fields such as agricultural and life sciences, arts, busines …
  • Life Care Centers of America Inc:企業の戦略的SWOT分析
    Life Care Centers of America Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Ethypharm SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Ethypharm SA (Ethypharm), a subsidiary of Astorg Partners is a pharmaceutical company that develops and manufactures drugs for the treatment of pain, gastrointestinal, cancer, cardiovascular and central nervous system diseases. The company provides products such as ibuprofen, paracetamol, pr …
  • Wentworth Resources Ltd (WRL):企業の財務・戦略的SWOT分析
    Wentworth Resources Ltd (WRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Biogen Inc (BIIB):企業の財務・戦略的SWOT分析
    Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Petsec Energy Ltd (PSA):石油・ガス:M&Aディール及び事業提携情報
    Summary Petsec Energy Ltd (Petsec Energy) is an oil and gas company that offers oil and gas exploration, development, and production. The Company holds interests in two oil and gas production fields located onshore Louisiana, the US in Mystic Bayou and Jeanerette Fields. It provides leases, explorat …
  • Banesco Banco Universal C.A.:企業の戦略・SWOT・財務情報
    Banesco Banco Universal C.A. - Strategy, SWOT and Corporate Finance Report Summary Banesco Banco Universal C.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Rexnord Corp (RXN):企業の財務・戦略的SWOT分析
    Rexnord Corp (RXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • MediGene AG (MDG1):企業の財務・戦略的SWOT分析
    MediGene AG (MDG1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • BASF Corp-エネルギー分野:企業M&A・提携分析
    Summary BASF Corp (BASF), a subsidiary of BASF SE, is a chemical manufacturing company. Its product portfolio includes petrochemicals, monomers, intermediates, dispersions and pigments, care chemicals, nutrition and health products, paper chemicals, performance chemicals, catalysts, construction che …
  • Sumitomo Heavy Industries, Ltd.:企業の戦略・SWOT・財務情報
    Sumitomo Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Heavy Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Randox Laboratories Ltd-医療機器分野:企業M&A・提携分析
    Summary Randox Laboratories Ltd (Randox) is a clinical diagnostic company that manufactures and provides clinical diagnostic solutions to laboratories. The company’s products include biochip analyzers, biochip immunoassays, clinical chemistry analyzers and diagnostic reagents among others. It offers …
  • Syros Pharmaceuticals Inc (SYRS):企業の財務・戦略的SWOT分析
    Summary Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company offers its pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that …
  • CFM International, Inc.:企業の戦略・SWOT・財務情報
    CFM International, Inc. - Strategy, SWOT and Corporate Finance Report Summary CFM International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Banco Pan SA (BPAN4):企業の財務・戦略的SWOT分析
    Banco Pan SA (BPAN4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Emsland Group:企業の戦略・SWOT・財務分析
    Emsland Group - Strategy, SWOT and Corporate Finance Report Summary Emsland Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Muehlbauer Holding AG & Co. KGaA (MUB):企業の財務・戦略的SWOT分析
    Muehlbauer Holding AG & Co. KGaA (MUB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆